There are 449 resources available
Assessing response and clinical benefit after NEOAdjuvant IO: The oncologist perspective
Presenter: Marina Garassino
Session: Challenges with neo-adjuvant IO
Resources:
Slides
Webcast
Invited Discussant 3MO and 5MO
Presenter: Zofia Piotrowska
Session: Mini Oral session 2
Resources:
Slides
Webcast
Q&A
Session: Mini Oral session 2
Resources:
Webcast
Q&A and discussion
Session: Challenges with neo-adjuvant IO
Resources:
Webcast
6MO - Subcutaneous amivantamab administered every 4 weeks (Q4W) in patients with advanced solid malignancies: The phase Ib PALOMA study
Presenter: Natasha Leighl
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
244MO - Primary results from IMscin002: A study to evaluate patient (pt)- and healthcare professional (HCP)-reported preferences for atezolizumab (atezo) subcutaneous (SC) vs intravenous (IV) for the treatment of NSCLC
Presenter: Federico Cappuzzo
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
Invited Discussant 6MO and 244MO
Presenter: Hazel O'Sullivan
Session: Mini Oral session 2
Resources:
Slides
Webcast
Q&A
Session: Mini Oral session 2
Resources:
Webcast
4O - First-line (1L) osimertinib (osi) ± platinum-pemetrexed in EGFR-mutated (EGFRm) advanced NSCLC: FLAURA2 post-progression outcomes
Presenter: Natalia Isabel Valdiviezo Lama
Session: Proffered Paper session
Resources:
Abstract
Slides
Webcast
Invited discussant 4O
Presenter: Joop De Langen
Session: Proffered Paper session
Resources:
Slides
Webcast